Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Clinical Cancer Research.
Times cited: 66
Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions: Conversion from an antiproliferative to profibrotic response to TGF-β1.
Journal of Clinical Investigation.
Times cited: 158